Stocks That Hit 52-Week Lows On Thursday
Thursday morning, 173 companies reached new 52-week lows.
Cathie Wood’s ARK Invest Posts Fund Purchases For Wednesday, Aug. 18, 2021: PATH, PLTR, Z, RPTX, SURF, QSI, VCYT, PFE, NVTA, ZY, MASS, EXAS, DYNS, CRSP, SMFR, TSP, SRNG, SGFY, NTLA, BEAM, FATE, EDIT, AVAV, BLDE, KMTUY, MKFG, CND, GENI, KVSB, LPSN
UiPath (PATH) - 80,400 Shares
Palantir Technologies (PLTR) - 93,189
Zillow Group (Z) - 21,507
Repare Therapeutics (RPTX) - 3,791
Surface Oncology (SURF) - 41,741
Quantum-Si (QSI) - 130,116
Veracyte (VCYT) -
Cathie Wood’s ARK Invest Posts Fund Purchases For Tuesday, Aug. 17, 2021: PLTR, Z, RPTX, VCYT, QSI, ZY, NTLA, MASS, EDIT, DYNS, CRSP, BLI, SMFR, FATE, EXAS, SGFY, BEAM, NVTA, AVAV, MKFG, BLDE, KMTUY, RBLX, LPSN, KVSB, CND
Palantir Technologies (PLTR) - 476,114 Shares
Zillow Group (Z) - 2,800
Repare Therapeutics (RPTX) - 8,967
Veracyte (VCYT) - 40,152
Quantum-Si (QSI) - 163,972
Zymergen (ZY) - 136,853
Intellia Therapeutics (NTLA) -
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 16)
10 Health Care Stocks Showing Unusual Options Activity In Today’s Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. Unusual trading activity could push option prices to exaggerated or underestimated levels.
Invitae Corp. Shares Up 3%; Bloomberg Reported Late Friday ‘Exact Sciences Said to Approach Invitae About Merger’; Exact Sciences Shares Down ~1%
https://www.bloomberg.com/news/articles/2021-08-06/exact-sciences-said-to-approach-invitae-about-potential-merger
20 Stocks Moving in Monday’s Pre-Market Session
Gainers
Windtree Therapeutics, Inc. (NASDAQ: WINT) shares rose 55.8% to $2.82 in pre-market trading after dropping over 10% on Friday. The company recently reported a wider loss for its second quarter.
Morgan Stanley Maintains Equal-Weight on Invitae, Lowers Price Target to $40
Morgan Stanley maintains Invitae (NYSE:NVTA) with a Equal-Weight and lowers the price target from $41 to $40.
